early breast cancer

systematic review meta-analysis network meta-analysis

Select HER2 inhibitorsmonoclonal antibody HER2 positiveuncoded clinical condition ***       aaaafter chemotherapyduring chemotherapytrastuzumab pertuzumabtrastuzumab      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (3) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death
HER2 inhibitors
pertuzumab
Aphinity    NCT	pertuzumab	placebo			Low risk of bias	-
trastuzumab
NSABP B31, 2005	trastuzumab	control				suggesting
BCIRG006, 2013	trastuzumab	control				suggesting
Buzdar, 2005	trastuzumab	control				suggesting
FinHer, 2006	trastuzumab	control				negative
HERA, 2005	trastuzumab	control				suggesting
N9831, 2005	trastuzumab	control				suggesting
NOAH, 2010	trastuzumab	control				negative
PACS-04, 2009	trastuzumab	control				suggesting
N9831 (1)	trastuzumab	control				suggesting
N9831 (2)	trastuzumab	control				suggesting
FinHer (1)	trastuzumab	control				negative
monoclonal antibody
not classified
HERA (BIG 01-01) 2-years, 2005    NCT	trastuzumab					-
HERA (BIG 01-01) 1-year, 2005    NCT	trastuzumab	control			Risk of bias	suggesting
NCCTG N9831(C vs A)	trastuzumab	control				suggesting
NSABP B-31	trastuzumab during chemotherapy	control				suggesting